Matches in SemOpenAlex for { <https://semopenalex.org/work/W2318786091> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W2318786091 abstract "To review a new anticholinergic for overactive bladder undergoing review by the U.S. Food and Drug Administration, solifenacin.A MEDLINE/PUBMED search was conducted to identify pertinent studies in the English language. In addition, proceedings of meetings of the Incontinence Society, European Association of Urology, American Urological Association, and American College of Obstetrics and Gynecology were reviewed for relevant abstracts. Additional references were obtained from the bibliographies of these sources. Data over the time period of 1986 through October 2003 were reviewed.All studies evaluating any aspect of solifenacin in animals and humans.Preclinical studies demonstrated that solifenacin was an antagonist at muscarinic cholinergic M1, M2, and M3 receptors. On the basis of comparative preclinical studies evaluating the effects of solifenacin and oxybutynin on guinea pig detrusor muscle cells, mouse submandibular gland cells, and the intact rat, solifenacin was felt to be a uroselective antimuscarinic. Solifenacin is predominantly eliminated via metabolism, with urinary excretion of parent compound being less than 10%. Solifenacin, dosed once daily, is significantly superior to placebo in reducing the number of micturitions, urge episodes, and urge incontinence episodes per day and increasing the volume voided per micturition. In two active-controlled trials, solifenacin was at least equivalent to tolterodine in efficacy and tolerability. The most problematic adverse effects of solifenacin are the anticholinergic effects of dry mouth, blurred vision, and constipation.Although promising in preclinical studies, the uroselectivity of the anticholinergic activity of solifenacin has not been validated in clinical trials. No comparative efficacy/tolerability data with oxybutynin are available. On the basis of available data, solifenacin does not appear to be a substantial advance upon existing anticholinergics in the management of overactive bladder." @default.
- W2318786091 created "2016-06-24" @default.
- W2318786091 creator A5020501067 @default.
- W2318786091 date "2004-05-01" @default.
- W2318786091 modified "2023-09-26" @default.
- W2318786091 title "Drug Forecast—Solifenacin: An Investigational Anticholinergic for Overactive Bladder" @default.
- W2318786091 cites W1992337831 @default.
- W2318786091 cites W2034685985 @default.
- W2318786091 cites W2062330428 @default.
- W2318786091 cites W2091111772 @default.
- W2318786091 cites W2094952568 @default.
- W2318786091 cites W2119809361 @default.
- W2318786091 doi "https://doi.org/10.4140/tcp.n.2004.437" @default.
- W2318786091 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16553482" @default.
- W2318786091 hasPublicationYear "2004" @default.
- W2318786091 type Work @default.
- W2318786091 sameAs 2318786091 @default.
- W2318786091 citedByCount "1" @default.
- W2318786091 crossrefType "journal-article" @default.
- W2318786091 hasAuthorship W2318786091A5020501067 @default.
- W2318786091 hasConcept C126322002 @default.
- W2318786091 hasConcept C126894567 @default.
- W2318786091 hasConcept C142724271 @default.
- W2318786091 hasConcept C204787440 @default.
- W2318786091 hasConcept C2777844464 @default.
- W2318786091 hasConcept C2777912814 @default.
- W2318786091 hasConcept C2778164427 @default.
- W2318786091 hasConcept C2778531004 @default.
- W2318786091 hasConcept C2778689640 @default.
- W2318786091 hasConcept C2778941218 @default.
- W2318786091 hasConcept C2779502394 @default.
- W2318786091 hasConcept C2781020410 @default.
- W2318786091 hasConcept C71924100 @default.
- W2318786091 hasConcept C98274493 @default.
- W2318786091 hasConceptScore W2318786091C126322002 @default.
- W2318786091 hasConceptScore W2318786091C126894567 @default.
- W2318786091 hasConceptScore W2318786091C142724271 @default.
- W2318786091 hasConceptScore W2318786091C204787440 @default.
- W2318786091 hasConceptScore W2318786091C2777844464 @default.
- W2318786091 hasConceptScore W2318786091C2777912814 @default.
- W2318786091 hasConceptScore W2318786091C2778164427 @default.
- W2318786091 hasConceptScore W2318786091C2778531004 @default.
- W2318786091 hasConceptScore W2318786091C2778689640 @default.
- W2318786091 hasConceptScore W2318786091C2778941218 @default.
- W2318786091 hasConceptScore W2318786091C2779502394 @default.
- W2318786091 hasConceptScore W2318786091C2781020410 @default.
- W2318786091 hasConceptScore W2318786091C71924100 @default.
- W2318786091 hasConceptScore W2318786091C98274493 @default.
- W2318786091 hasLocation W23187860911 @default.
- W2318786091 hasLocation W23187860912 @default.
- W2318786091 hasOpenAccess W2318786091 @default.
- W2318786091 hasPrimaryLocation W23187860911 @default.
- W2318786091 hasRelatedWork W134550863 @default.
- W2318786091 hasRelatedWork W1504077734 @default.
- W2318786091 hasRelatedWork W1507298952 @default.
- W2318786091 hasRelatedWork W1559663349 @default.
- W2318786091 hasRelatedWork W2079785628 @default.
- W2318786091 hasRelatedWork W2081386520 @default.
- W2318786091 hasRelatedWork W2137090901 @default.
- W2318786091 hasRelatedWork W2329733262 @default.
- W2318786091 hasRelatedWork W2406257615 @default.
- W2318786091 hasRelatedWork W43306833 @default.
- W2318786091 isParatext "false" @default.
- W2318786091 isRetracted "false" @default.
- W2318786091 magId "2318786091" @default.
- W2318786091 workType "article" @default.